Evommune EVMN Ratios & Valuation
| FY'25 | FY'24 | ||
|---|---|---|---|
| Profitability | |||
| Gross margin | 52.7%— | —— | |
| Operating margin | -21.2%— | —— | |
| Returns | |||
| Return on invested capital | -102.5%— | —— | |
| Efficiency | |||
| Asset turnover | 0.8×— | —— | |
| Liquidity | |||
| Current ratio | 0.9×+0.4× | 0.5×— | |
| Leverage | |||
| Debt-to-equity | 1.4×— | —— | |
| Per Share | |||
| Book value per share | $0.02+202% | -$0.02— | |
| Valuation | |||
| Market capitalization | $848.59M+39.5% | —— | |
| Price / sales | 127.3×— | —— | |
| Price / book | 350.1×— | —— |
Questions, answered.
- What are Evommune 's profit margins?
- Evommune (EVMN) runs a 53.7% gross margin and a -30.7% operating margin, with a -90.1% net margin.
- Where do Evommune 's ratios come from?
- Every ratio is computed from Evommune 's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
